Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mercadante, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mercadante, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The role of morphine glucuronides in cancer pain

Sebastiano Mercadante

Pain Relief and Palliative Care, SAMOT, Palermo

Morphine metabolites are involved in various ways in determining the complex effects of morphine, both favourable and adverse, and may complicate the clinical use of morphine in the treatment of cancer pain. The production and effects of the principal morphine metabolites, morphine-3-glucuronide and morphine-6-glucuronide, in both normal and pathological states have been reviewed in the current literature. Therapeutic implications are also reviewed on the basis of experimental and clinical reports. The presence of these metabolites should be recognized in the chronic treatment of cancer pain with morphine, especially in the presence of renal impairment, and should be considered to have an important influence on opioid responsiveness, defined as a balance between the achievement of an optimal analgesia and the occurrence of adverse effects.

Key Words: drug toxicity • morphine • neoplasms • pain

Palliative Medicine, Vol. 13, No. 2, 95-104 (1999)
DOI: 10.1191/026921699678158579
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
R. H Boger
Renal impairment: a challenge for opioid treatment? The role of buprenorphine
Palliative Medicine, January 1, 2006; 20(8_suppl): 17 - 23.
[Abstract] [PDF]

Home page
 Palliat MedHome page
M. Takahashi, T. Ohara, H. Yamanaka, A. Shimada, T. Nakaho, and M. Yamamuro
The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment
Palliative Medicine, December 1, 2003; 17(8): 673 - 678.
[Abstract] [PDF]

Home page
 Palliat MedHome page
P. Klepstad, P. C Borchgrevink, O. Dale, K. Zahlsen, T. Aamo, P. Fayers, B. Fougner, and S. Kaasa
Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients
Palliative Medicine, December 1, 2003; 17(8): 679 - 687.
[Abstract] [PDF]